Navigation Links
Akela Pharma provides corporate update
Date:12/20/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that due to unfavorable market conditions, particularly in the small and micro-cap sector, it has decided to abandon its US public offering initiative. The Company is currently contemplating other financing options. It is still the Company's intention to list its shares on a US exchange.

Akela also announces it has already started to implement significant cost reduction measures to bring its cash burn rate in line with its current and expected financial resources. The Company will primarily focus its R&D activities on its core programs. PharmaForm, the Company's drug formulation and manufacturing subsidiary located in Austin, Texas, is currently experiencing substantial growth, and is expected to contribute towards the Company's operating cash flow in the near term.

"Although the latest unfavorable market conditions did not allow us to complete our US public offering as originally planned, we remain extremely confident about the appeal and commercial potential of our products and platforms. We have aligned our corporate focus with our financial resources to ensure optimal returns on our core activities" said Dr Halvor Jaeger, CEO of Akela Pharma Inc.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE AKELA PHARMA INC.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Akela Pharma reports results for third quarter of fiscal 2007
5. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
6. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
7. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
(Date:6/24/2016)... IL (PRWEB) , ... June 24, 2016 , ... ... Beard, DDS, and Randall Markarian, DDS, are co-chairs for the Illinois State Dental ... clinic Friday-Saturday, July 15-16 at the Gateway Convention Center in Collinsville. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology: